Diasorin (DIA) Stock Price, Fundamentals & Analysis

What DIA does

DiaSorin (DIA) is a healthcare company headquartered in Saluggia, Italy, listed on the Borsa Italiana. It operates in the Diagnostics & Research industry and engages in the research, development, manufacturing, and distribution of immunodiagnostics and molecular diagnostics testing kits across Europe, North America, and internationally. Its product portfolio includes the LIAISON XL and LIAISON XS platforms for immunoassays covering infectious diseases, gastrointestinal diseases, hepatitis, retroviruses, endocrinology, metabolic disorders, tumor markers, and oncology. The company also offers Simplexa, a congenital CMV direct kit for detecting cytomegalovirus DNA in saliva swabs and urine specimens, as well as the LIAISON PLEX Respiratory Flex Assay and LIAISON PLEX Yeast Blood Culture Assay. Additionally, DiaSorin provides the xMAP technology platform for in vitro diagnostics. Founded in 1968, it is headquartered in Saluggia, Italy.

Key numbers explained

• Market: DiaSorin trades on the Borsa Italiana, the main stock exchange of Italy.
• Price and daily change: The stock is currently priced at 78.8 EUR, with a daily change of +0.33%.
• Market capitalization: The company's market cap stands at 3.9 billion EUR, reflecting its size in the market.
• Valuation ratios: The trailing P/E ratio is 29, while the forward P/E ratio (based on expected earnings) is 18.4. The earnings per share (trailing 12 months) is 2.72 EUR.
• Dividend: The dividend yield is 1.65%, with an ex-dividend date of May 18, 2026. The company pays out 48% of its earnings as dividends.
• Risk and volatility: The beta is 0.7, indicating lower volatility than the market. The 52-week price range is 52.34 – 80.38 EUR, and the stock has changed 4.3% over the last 52 weeks.
• Financials: Trailing 12-month revenue is 1.18 billion EUR (growth of 2.7% YoY), with a profit margin of 11.9% and an operating margin of 22.4%. Return on equity is 9.2%, and the debt-to